EXCHANGE AGREEMENT

EXCHANGE AGREEMENT (this “Agreement”), dated as of July 29, 2026, among Jersey Mike’s Subs Inc., a Delaware corporation, Jersey Mike’s HoldCo, LLC, a Delaware limited liability company, and the holders, other than the Corporation (as defined herein), of Common Units (as defined herein) from time to time party hereto.

WHEREAS, the parties hereto desire to provide for the exchange of Common Units for shares of Class A Common Stock (as defined herein), on the terms and subject to the conditions set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and undertakings contained herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

ARTICLE I

SECTION 1.1. Definitions

The following definitions shall be for all purposes, unless otherwise clearly indicated to the contrary, applied to the terms used in this Agreement.

“Agreement” has the meaning set forth in the preamble of this Agreement.

…

TAX RECEIVABLE AGREEMENT

between

JERSEY MIKE’S SUBS INC.

and

THE PERSONS NAMED HEREIN

Dated as of July 29, 2026

---

TABLE OF CONTENTS

			Page
ARTICLE I DEFINITIONS			2
SECTION 1.1	Definitions		2

…

______________________________________

JERSEY MIKE’S Holdco, LLC

A Delaware Limited Liability Company

______________________________________

THIRD AMENDED AND RESTATED

LIMITED LIABILITY COMPANY AGREEMENT

Dated as of July 29, 2026

THE LIMITED LIABILITY COMPANY UNITS EVIDENCED BY THIS THIRD AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933 OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH LIMITED LIABILITY COMPANY UNITS MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE DISPOSED OF AT ANY TIME WITHOUT EFFECTIVE REGISTRATION UNDER SUCH ACT AND LAWS OR EXEMPTION THEREFROM, AND COMPLIANCE WITH THE OTHER RESTRICTIONS ON TRANSFERABILITY SET FORTH HEREIN. PURCHASERS OF LIMITED LIABILITY COMPANY UNITS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THEIR INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

---

TABLE OF CONTENTS

Page

…

STOCKHOLDERS AGREEMENT

DATED AS OF JULY 29, 2026

BETWEEN

JERSEY MIKE’S SUBS INC.

AND

THE OTHER PARTIES HERETO

---

TABLE OF CONTENTS

Page

ARTICLE I. INTRODUCTORY MATTERS		1
1.1	Defined Terms	1
1.2	Construction	5
ARTICLE II. CORPORATE GOVERNANCE MATTERS		5
2.1	Election of Directors	5
2.2	Compensation	7

…

**AMENDMENT TO **

**SEVERANCE LETTER AGREEMENT **

This amendment to the severance letter agreement (this “Amendment”) is entered into as of August [•], 2026, by and between Lantheus Medical Imaging, Inc., a Delaware corporation (the “Company”), and [•] (“Executive”).

WHEREAS, the Company and Executive are parties to a severance letter agreement, dated as of [•] (the “Severance Letter Agreement”);

WHEREAS, Section 12 of the Severance Letter Agreement provides that it may be amended by a written instrument signed by the parties; and

WHEREAS, the parties wish to amend the Severance Letter Agreement to clarify the treatment of compensation payable to Executive upon a Qualifying Termination (as defined in the Severance Letter Agreement) in connection with that certain Agreement and Plan of Merger, being entered into by and among Curium US Holdings LLC, a Delaware limited liability company, Lantheus Holdings, Inc. and the other parties thereto.

…

[DATE]

***VIA ELECTRONIC MAIL ***

[NAME]

[ADDRESS]

**Re: Transaction Bonus **

As you know, Lantheus Holdings, Inc. (“Lantheus”) is entering into an Agreement and Plan of Merger with Curium US Holdings LLC and the other parties thereto (the “Merger Agreement” and the transactions contemplated by the Merger Agreement, the “Merger”).

In recognition of your work and contributions to Lantheus and its subsidiaries (collectively, the “Company”) in connection with the Merger prior to the Effective Time (as defined in the Merger Agreement), you will be eligible to receive a bonus in an amount equal to $[•] (the “Transaction Bonus”), subject to the terms and conditions of this letter agreement (this “Letter”). If for any reason the Merger Agreement terminates prior to the closing of the Merger (the “Closing”) or the Closing does not occur, then this Letter shall be null and void ab initio and of no force or effect.

…

JOINDER AND THIRTEENTH AMENDMENT AGREEMENT, dated as of July 31, 2026 (this “Amendment”), to Second Amended and Restated Credit Agreement, dated as of February 15, 2017, as amended by Amendment No. 1, dated as of November 22, 2017, as amended by the Joinder and Amendment Agreement, dated as of June 4, 2019, as amended by Amendment No. 3, dated as of October 3, 2019, as amended by Joinder and Fourth Amendment Agreement, dated as of August 10, 2020, as amended by Fifth Amendment Agreement, dated as of March 8, 2021, as amended by Joinder and Sixth Amendment Agreement, dated as of November 10, 2022, as amended by the Seventh Amendment Agreement, dated as of May 5, 2023, as amended by the Eighth Amendment Agreement, dated as of July 19, 2023, as amended by the Ninth Amendment Agreement, dated as August 15, 2023, as amended by the Tenth Amendment Agreement, dated as of January 22, 2024, as amended by the Eleventh Amendment Agreement, dated as of May 31, 2024, as amended by the Twelfth Amendment Agreement, dated as of December 16, 2024 (and as further amended, restated, supplemented or oth

…

** **

SEPARATION, RESIGNATION AND EXECUTIVE TRANSITION AGREEMENT

** **

This SEPARATION, RESIGNATION AND EXECUTIVE TRANSITION AGREEMENT (this “Agreement”) is made and entered into as of the 31st day of July 2026 (the “Effective Date”) by and between VIVOS THERAPEUTICS, INC., a Delaware corporation having its principal place of business at 7921 Southpark Plaza, Suite 210, Littleton, CO 80120 (the “Company”) and BRADFORD AMMAN, an individual currently residing in the City of Littleton, Colorado (the “Executive”). As used herein, the term “Parties” shall be used to refer to the Company and Executive jointly.

RECITALS

** **

WHEREAS, the Company and Executive are parties to that certain Amended and Restated Executive Employment Agreement dated January 1, 2025 (the “Employment Agreement”), pursuant to which Executive serves as the Company’s Chief Financial Officer (“CFO”);

…

** **

Exhibit 10.2

** **

MASTER SERVICES AGREEMENT

between The CFO Portal, LLC and Vivos Therapeutics, Inc.

This Master Services Agreement (the “Agreement”) is entered into as of July 31, 2026 (the “Effective Date”) by and between The CFO Portal, LLC, a Florida limited liability company (“Provider”), and Vivos Therapeutics, Inc., a Delaware corporation with its principal place of business at 7921 Southpark Plaza, Suite 210, Littleton, CO 80120 (“Client” or “Company”). Provider and Client are referred to herein individually as a “Party” and collectively as the “Parties”.

RECITALS

A. Client is a publicly traded corporation listed on The Nasdaq Stock Market LLC under the ticker symbol “VVOS.”

B. Provider is a professional services firm specializing in fractional and managed Chief Financial Officer services for public microcap companies, including SEC reporting, internal controls, capital markets, and audit support.

…

FIRST AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTE

This FIRST AMENDMENT (this “First Amendment”) to the Senior Secured Convertible Note dated July 29, 2025 (the “Note”), is dated effective as of July 29, 2026, by and between Capstone Holding Corp., a Delaware corporation (the “Company”), and the purchaser of the Note (the “Holder” and, together with the Company, the “Parties”).

WHEREAS, the Company issued the Note in the original principal amount of approximately $3,545,712.42 with a 8.34% original issue discount in favor of the Holder on July 29, 2025;

WHEREAS, the Maturity Date under the Note is currently defined as July 29, 2026;

WHEREAS, the Company and the Holder desire to amend the Note to extend the Maturity Date and modify the definition contained therein;

WHEREAS, pursuant to Section 17 of the Note, the Company and the Holder desire to amend the terms of the Note as set forth herein;

…

** **

Cycurion, Inc.

1640 Boro Place, Suite 420C

McLean, Virginia

July 30, 2026

To the Holder of Common Stock Purchase Warrants Issued in December 2025

Re: Inducement Offer to Exercise Existing Shares of Common Stock Purchase Warrants

Dear Holder:

Cycurion, Inc. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder”, “you” or similar terminology) the opportunity to receive new common stock purchase warrants (the “New Warrants”) to purchase up to 5,012,159 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), which is equal to 150% of the number of shares of Common Stock issuable upon exercise of a common stock purchase warrant to purchase up to 3,341,439 shares of Common Stock at an exercise price of $3.62 per share issued to you on December 5, 2025 (the “Existing Warrants”), as more particularly set forth on the signature page hereto, in consideration for exercising for cash all such Existing Warrants. The issuance of the shares of Common Stock underlying the Existing Warrants have been registered pursua

…

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of July 31, 2026, between Moleculin Biotech, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I.
DEFINITIONS

…